The Catalent Applied Drug Delivery Institute and the American Association of Pharmaceutical Scientists (AAPS), today announced the winners of the “Global Academic Competition for Life Science Leaders of Tomorrow.”
Somerset, N.J. – July 23, 2015 — The Catalent Applied Drug Delivery Institute and the American Association of Pharmaceutical Scientists (AAPS) today announced the winners of the “Global Academic Competition for Life Science Leaders of Tomorrow.”
The competition aims to identify emerging scientific talent, foster drug delivery education and reward academic excellence. The four winning entries, chosen from leading U.S. and international European universities with graduate programs in pharmaceutical science, each receive $2,000 (USD), a complimentary, one-year membership to the AAPS, and the potential opportunity to have their review published in a peer-reviewed journal.
The 2015 winners are:
- Marius Hittinger and Nicole Schneider-Daum from Helmholtz-Institute for Pharmaceutical Research Saarland, for their submission “Cell And Tissue-Based in vitro Improving the Development of Oral Inhalation Drug Products”
- Mania Dorrani and Bozena Michniak-Kohn of Rutgers University for “Topical siRNA Delivery: Challenges and Prospects”
- Harini Venkata Krishnan and Shilpa Sant from University of Pittsburgh for “Three Dimensional Cell Cultures: Opportunities for Drug Discovery and Development”
- Zhijian He, Daria Alakhova, Alexander V. Kabanov University of North Carolina at Chapel Hill for “Nanoformulations of Taxanes.”
“Our goal, for the competition, and for the Institute itself, is to foster education, collaboration and adoption of innovative drug delivery technologies to develop better treatments for patients,” commented Sharon Johnson, Catalent’s Senior VP, Quality, Product Development & Regulatory Affairs. “The standard of entries in this year’s competition was exceptional. We congratulate all the winners and look forward to sharing their reviews with the wider drug delivery community.”
Established in 2012, the Catalent Applied Drug Delivery Institute employs a multi-tiered approach to accelerate the adoption of advanced drug delivery technologies through industry and academic collaboration, research, education, and the sharing of information. In June 2014, the Institute created the Non-Invasive Macro-Molecule Drug Delivery Consortium (NMDC) and established a number of working groups looking at alternative delivery routes to injection for biologics and other large molecule therapeutics. The working groups include oral, pulmonary/nasal, ocular and transdermal delivery and welcome new members who wish to support innovation in non-invasive drug delivery.
The Drug Delivery Institute continues to encourage and promote collaboration in various areas of drug delivery and from 18th to 21st February, 2016, will host the Non-Invasive Delivery of Macromolecules Conference 2016 at the Omni La Costa Resort & Spa, Carlsbad, San Diego, USA. The goal of the meeting is to provide an open and creative forum for academic and industrial scientists to discuss the spectrum of activities, from concept to clinical testing, required for successful development of clinical products.
For more details on the Catalent Institute, visit www.drugdeliveryinstitute.com
+44 (0)7580 041073
About The Catalent Applied Drug Delivery Institute
Catalent’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments and foster industry collaboration on major issues pertaining to drug development, formulation and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,600 people, including over 1,000 scientists, at 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com